Roberto Mignone Sells 286,000 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) Stock

Teva Pharmaceutical Industries Limited (NYSE:TEVA - Get Free Report) Director Roberto Mignone sold 286,000 shares of the company's stock in a transaction dated Friday, December 20th. The stock was sold at an average price of $22.01, for a total transaction of $6,294,860.00. Following the transaction, the director now owns 695,000 shares of the company's stock, valued at approximately $15,296,950. This trade represents a 29.15 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Teva Pharmaceutical Industries Trading Up 0.9 %

TEVA stock traded up $0.20 during trading on Thursday, reaching $22.62. 7,484,542 shares of the stock were exchanged, compared to its average volume of 9,422,448. The company has a current ratio of 0.89, a quick ratio of 0.61 and a debt-to-equity ratio of 2.57. The firm has a market capitalization of $25.63 billion, a price-to-earnings ratio of -26.61, a P/E/G ratio of 0.99 and a beta of 0.79. The business has a 50 day moving average price of $18.06 and a 200-day moving average price of $17.64. Teva Pharmaceutical Industries Limited has a 1 year low of $10.39 and a 1 year high of $22.80.

Analyst Upgrades and Downgrades

Several analysts recently commented on the company. UBS Group boosted their price target on Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the stock a "buy" rating in a research report on Tuesday, September 3rd. StockNews.com lowered shares of Teva Pharmaceutical Industries from a "strong-buy" rating to a "buy" rating in a report on Wednesday, December 18th. Barclays increased their target price on shares of Teva Pharmaceutical Industries from $25.00 to $28.00 and gave the company an "overweight" rating in a research report on Wednesday, December 18th. Finally, JPMorgan Chase & Co. boosted their price target on shares of Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the stock a "neutral" rating in a research report on Monday, October 21st. Two investment analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $20.88.

Institutional Investors Weigh In On Teva Pharmaceutical Industries

A number of institutional investors and hedge funds have recently added to or reduced their stakes in TEVA. UMB Bank n.a. lifted its holdings in shares of Teva Pharmaceutical Industries by 555.6% in the 3rd quarter. UMB Bank n.a. now owns 2,439 shares of the company's stock worth $44,000 after acquiring an additional 2,067 shares during the last quarter. Smithfield Trust Co lifted its stake in Teva Pharmaceutical Industries by 55.7% during the third quarter. Smithfield Trust Co now owns 2,739 shares of the company's stock worth $50,000 after purchasing an additional 980 shares in the last quarter. Wilmington Savings Fund Society FSB acquired a new position in Teva Pharmaceutical Industries in the 3rd quarter valued at about $50,000. Claro Advisors LLC purchased a new position in shares of Teva Pharmaceutical Industries in the 3rd quarter valued at about $52,000. Finally, Mark Sheptoff Financial Planning LLC acquired a new stake in shares of Teva Pharmaceutical Industries during the 2nd quarter worth about $57,000. Hedge funds and other institutional investors own 54.05% of the company's stock.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.